Stockscreener 앱 받기
2.07
0.96%
-0.02
시간 외 거래:
2.07
Proqr Therapeutics N V 주식(PRQR)의 최신 뉴스
CureVac NV (CVAC) Peer Comparison – Compare with Others - Value Research
ProQR to Participate in Upcoming Investor Conferences in September 2026 - markets.businessinsider.com
ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
ProQR Therapeutics N.V.ADR Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
ProQR Therapeutics NV (PRQR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Certain Warrants of ProQR Therapeutics N.V. are subject to a Lock-Up Agreement Ending on 24-AUG-2026. - marketscreener.com
Certain Common Stock of ProQR Therapeutics N.V. are subject to a Lock-Up Agreement Ending on 24-AUG-2026. - marketscreener.com
ProQR Therapeutics: Buy For Axiomer RNA Tech Validation And Other Catalysts (NASDAQ:PRQR) - Seeking Alpha
ProQR Therapeutics starts with Buy rating on st... - Pluang
Price to sales forward of ProQR Therapeutics N.V. – FWB:0PQ - TradingView
PRQR Looks 1.8% Undervalued on GF Value™ at $2.45 - GuruFocus
PRQR Initiates Coverage by B of A Securities -- Price Target Ann - GuruFocus
ProQR a new buy at BoA on RNA-editing platform - Seeking Alpha
ProQR Therapeutics (NASDAQ:PRQR) Earns Buy Rating from Analysts at Bank of America - MarketBeat
BofA Securities initiates ProQR stock with buy on liver therapy By Investing.com - Investing.com India
BofA Securities initiates ProQR stock with buy on liver therapy - Investing.com
ProQR (PRQR) Levels: Climbs 3.26% to $2.22 in the Latest Session; Key Range - vinanet.vn
HC Wainwright Expects Lower Earnings for ProQR Therapeutics - MarketBeat
ProQR Therapeutics Virtual Investor Event Transcript - GuruFocus
Equities Analysts Set Expectations for PRQR FY2030 Earnings - MarketBeat
H.C. Wainwright reiterates ProQR stock rating on platform data By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates ProQR stock rating on platform data - in.investing.com
ProQR Therapeutics (NASDAQ:PRQR) Rating Increased to Hold at Wall Street Zen - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Announces Earnings Results - MarketBeat
ProQR: Q2 Earnings Snapshot - KING5.com
symbol__ Stock Quote Price and Forecast - CNN
ProQR Therapeutics NV earnings beat by €0.03, revenue topped estimates - Investing.com Nigeria
ProQR Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
ProQR Therapeutics NV reports results for the quarter ended June 30Earnings Summary - TradingView
ProQR Reports Higher Revenue but Ongoing Losses in Second Quarter 2026 Results - TipRanks
ProQR Announces Second Quarter 2026 Operating and Financial Results - The Manila Times
ProQR Therapeutics Reports First Clinical Validation of Axiomer RNA Editing Platform, Positive AX-0810 Data and Upcoming Pipeline Milestones - Quiver Quantitative
ProQR Therapeutics N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
ProQR Therapeutics NV expected to post a loss of 11 cents a shareEarnings Preview - TradingView
ProQR Therapeutics (PRQR) Slips 3.5% as Shares Test Key Support ZoneReversal Trade - dars.gov.et
ProQR Therapeutics NV (PRQR) Stock News Today - TradingKey
ProQR Therapeutics NV (PRQR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Enterprise value to EBIT forward of ProQR Therapeutics N.V. – MUN:0PQ - TradingView
ProQR Therapeutics (PRQR) CEO de Boer Daniel Anton Buys 200,000 Shares, Signaling Confidence - GuruFocus
ProQR Therapeutics (PRQR) Surges 7% to $1.83 as Buyers Defend Key SupportAnalyst Downgrade Signals - vinanet.vn
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Proqr Therapeutics Insider Bought Shares Worth $353,960, According to a Recent SEC Filing - marketscreener.com
ProQR Therapeutics (PRQR) CEO boosts stake with 200,000-share buy - Stock Titan
ProQR Therapeutics N.V. Revenue Breakdown – NASDAQ:PRQR - TradingView
ProQR Therapeutics (PRQR) to Announce Earnings on Thursday - MarketBeat
Van Herk Investments Files Petition with the Enterprise Chamber of the Amsterdam Court of Appeal Against ProQR Therapeutics - marketscreener.com
ProQR Therapeutics (NASDAQ:PRQR) Director Bart Filius Buys 150,000 Shares - MarketBeat
ProQR Therapeutics N.V. Revenue Breakdown – LS:A12B97 - TradingView
ProQR Therapeutics NV (PRQR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PRQR|ProQR Therapeutics NV|Price:1.720|Chg%:-0.060 - TradingKey
PRQR|ProQR Therapeutics NV|Price:1.730|Chg%:+0.010 - TradingKey
ProQR Therapeutics NV (PRQR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ProQR Therapeutics NV (PRQR) Institutional Confidence - TradingKey
ProQR Therapeutics NV (PRQR) Balance Sheet - TradingKey
ProQR Therapeutics NV (PRQR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ProQR Therapeutics N.V. Revenue Breakdown – BMV:PRQR/N - TradingView
TradingKey - TradingKey
ProQR Therapeutics NV (PRQR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Eli Lilly (NYSE: LLY) reports 21.99M-share beneficial stake in ProQR Therapeutics - Stock Titan
0.86%
0.31%
자본화:
|
볼륨(24시간):